Hossein Borghaei, DO, MS is chief of Thoracic Oncology and professor of Hematology and Oncology at Fox Chase Cancer Center in Philadelphia, Pa. He is the Gloria and Edmund M. Dunn Chair in Thoracic Oncology and co-director of the Immune Monitoring Facility. His specialties include endobronchial disease, lung cancer, lung metastases, mesothelioma, and thymoma. In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic.
Dr. Borghaei is the co-chair of the thoracic committee at Eastern Cooperative Oncology Group (ECOG) and the chair of the LungMap trial (S1800/S1900). He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. He also is the recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, SITC and ECOG thoracic committee, as well as a member of the Cancer Signaling and Microenvironment research program at Fox Chase. Dr. Borghaei was named to the 2022 list of Highly Cited Researchers by Clarivate and named one of Philadelphia Magazine’s Top Doctors in 2022.
Dr. Borghaei completed his fellowship at Fox Chase Cancer Center and earned his degree from the Philadelphia College of Osteopathic Medicine. He completed his residency at Graduate Hospital in Philadelphia and earned his master’s degree in microbiology and immunology from Temple University.
